Efficacy and Safety of Telmisartan as Adjunctive Therapy in Alcohol Withdrawal Syndrome: A Randomized, Open-Label Controlled Trial
International Journal of Drug Delivery Technology · 10.04.2026 · 16 (10s)
DOI: 10.25258/ijddt.16.10s.37 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 10.04.2026. Verfasst von Tarun Gupta und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Alcohol withdrawal syndrome (AWS) is a common and potential serious complication of abrupt cessation of chronic alcohol consumption, marked by autonomic hyperactivity, neuropsychiatric symptoms, and the possibility of seizures or delirium. Benzodiazepines remain conventional therapy but are limited by oversedation, respiratory depression, and overuse. Emerging evidence suggests the brain renin-angiotensin system plays a crucial role in addiction biology. Telmisartan, a brain-penetrant angiotensin receptor blocker with partial PPARγ agonism, may affect neuroinflammation and dopaminergic transmission, suggesting its potential efficacy as an adjuvant treatment for AWS.
Methods
We conducted a prospective, randomized, open label study in people with AWS. Participants were randomly assigned to receive either chlordiazepoxide, telmisartan, or a combination of both for seven days, with standardized supportive care. CIWA-Ar was used to assess withdrawal intensity from baseline to Day 12. Secondary outcomes included short term abstinence, craving value, and biochemical investigation. ANOVA and chi-square test were used, and the analyses were performed in GraphPad Prism version 10.5.
Results
The combination arm experienced a significantly higher mean reduction in CIWA-Ar scores (about 11 points compared to 9 points with chlordiazepoxide and 7 points with telmisartan; p
Zitieren
APA
Gupta, T., Das, S., Maity, P., Kumari, P., Singh, R., & Goyal, S. (2026). Efficacy and Safety of Telmisartan as Adjunctive Therapy in Alcohol Withdrawal Syndrome: A Randomized, Open-Label Controlled Trial. International Journal of Drug Delivery Technology, 16(10s). https://doi.org/10.25258/ijddt.16.10s.37
Vancouver
Gupta T, Das S, Maity P, Kumari P, Singh R, Goyal S. Efficacy and Safety of Telmisartan as Adjunctive Therapy in Alcohol Withdrawal Syndrome: A Randomized, Open-Label Controlled Trial. International Journal of Drug Delivery Technology. 2026;16(10s). doi:10.25258/ijddt.16.10s.37
BibTeX
@article{Gupta2026,
author = {Gupta, Tarun and Das, Soumarshi and Maity, Prabir and Kumari, Pratima and Singh, Ravinder and Goyal, Sanjay},
title = {Efficacy and Safety of Telmisartan as Adjunctive Therapy in Alcohol Withdrawal Syndrome: A Randomized, Open-Label Controlled Trial},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {10s},
doi = {10.25258/ijddt.16.10s.37}
}
EUVIMED